We have developed a protein-based theranostic agent combining drug delivery with the ability to cross BBB and remain at cancer site via enhanced permeation and retention effect for glioblastoma. This near infrared-fluorinated-thermo responsive assembled protein (NIRF-TRAP) bears a near-infrared fluorescence tag, VivoS 680, for NIRF imaging and fluorinated amino acids detectable via magnetic resonance. NIRF-TRAP was characterized through dynamic light scattering revealing micelle assemblies ~30 nm in diameter. Through circular dichroism, we assessed its secondary structure. <i>In vivo</i> data suggests that NIRF-TRAP exhibits desirable pharmacokinetic properties with half-life of about 112 minutes and a favorable plasma retention time. Our studies also indicate successful delivery of the drug-encapsulating nanomaterials as a trojan horse across the generally impermeable BBB, potentially making it a powerful theranostic agent.

Engineering a near infrared fluorinated-thermo responsive assembled protein (NIRF-TRAP) for theranostic applications

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.